DataVXACS Applied Materials & InterfacesPaper
journal article·2023-04-12Open access

Feasibility of Coacervate-Like Nanostructure for Instant Drug Nanoformulation

Geyunjian H. Zhu, Mohammad Azharuddin, Bapan Pramanik, Karin Roberg, Sujoy Kumar Biswas, Padraig D’arcy, Meng Lu, Apanpreet Kaur, Alexander Chen, Ashis Kumar Dhara, Alexandru Chivu, Yunhui Zhuang, Andrew Baker, Xiewen Liu, David Fairen-Jimenez, Bismoy Mazumder, Rongjun Chen, Clemens F. Kaminski, Gabriele S. Kaminski Schierle, Jorma Hinkula, Nigel K. H. Slater, Hirak K. Patra

ACS Applied Materials & Interfaces· Volume 15· Issue 14
Publisher pageOpen full text
Source abstract

Abstract

Despite the enormous advancements in nanomedicine research, a limited number of nanoformulations are available on the market, and few have been translated to clinics. An easily scalable, sustainable, and cost-effective manufacturing strategy and long-term stability for storage are crucial for successful translation. Here, we report a system and method to instantly formulate NF achieved with a nanoscale polyelectrolyte coacervate-like system, consisting of anionic pseudopeptide poly(l-lysine isophthalamide) derivatives, polyethylenimine, and doxorubicin (Dox) via simple "mix-and-go" addition of precursor solutions in seconds. The coacervate-like nanosystem shows enhanced intracellular delivery of Dox to patient-derived multidrug-resistant (MDR) cells in 3D tumor spheroids. The results demonstrate the feasibility of an instant drug formulation using a coacervate-like nanosystem. We envisage that this technique can be widely utilized in the nanomedicine field to bypass the special requirement of large-scale production and elongated shelf life of nanomaterials.
Source: openalex_inverted_index · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Polymer Surface Interaction Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, United Kingdom

Department of Biomedical and Clinical Sciences (BKV), Linkoping University, Linköping 58183, Sweden

Department of Chemistry, Ben Gurion University of the Negev, Be’er Sheva 84105, Israel

Department of Otorhinolaryngology in Linköping, Anaesthetics, Operations and Specialty Surgery Center, Linköping University Hospital, Region Östergötland, Linköping 58185, Sweden

AIMP Laboratories, C86 Baishnabghata, Patuli Township, Kolkata 700094, India

Department of Chemical Engineering, Imperial College London, South Kensington Campus, London SW7 2AZ, United Kingdom

Department of Electrical Engineering, National Institute of Technology Durgapur, Durgapur 713209, West Bengal, India

Department of Surgical Biotechnology, Division of Surgery and Interventional Science, University College London, London NW3 2PF, United Kingdom

Funding

Imperial College London · Medical Research Council · Link?pings Universitet · British Council · Scheme for Promotion of Academic and Research Collaboration · H2020 Marie Sklodowska-Curie Actions · UK-India Education and Research Initiative

References (50)

Show source-provided references
1. 10.1021/nn900002m10.1021/nn900002m ↗
2. 10.1016/j.cccn.2005.03.01410.1016/j.cccn.2005.03.014 ↗
3. 10.1007/s11468-011-9228-110.1007/s11468-011-9228-1 ↗
4. 10.1016/j.arabjc.2017.05.01110.1016/j.arabjc.2017.05.011 ↗
5. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
6. 10.1016/j.ijpharm.2009.05.00410.1016/j.ijpharm.2009.05.004 ↗
7. 10.1039/C9CC01741K10.1039/C9CC01741K ↗
8. 10.1021/acsnano.7b0060910.1021/acsnano.7b00609 ↗
9. 10.1016/j.colsurfb.2012.08.05610.1016/j.colsurfb.2012.08.056 ↗
10. 10.1021/am403992b10.1021/am403992b ↗
11. 10.1016/j.ijpharm.2012.02.04210.1016/j.ijpharm.2012.02.042 ↗
12. 10.1016/j.drudis.2017.06.00810.1016/j.drudis.2017.06.008 ↗
13. 10.1021/ma902144k10.1021/ma902144k ↗
14. 10.1038/s41467-020-18815-910.1038/s41467-020-18815-9 ↗
15. 10.5962/bhl.title.452810.5962/bhl.title.4528 ↗
16. 10.1016/j.ijpharm.2006.07.01310.1016/j.ijpharm.2006.07.013 ↗
17. 10.1016/j.jconrel.2008.01.01510.1016/j.jconrel.2008.01.015 ↗
18. 10.1016/j.actbio.2013.09.01210.1016/j.actbio.2013.09.012 ↗
19. 10.1016/j.jconrel.2012.11.00410.1016/j.jconrel.2012.11.004 ↗
20. 10.1111/wrr.1231910.1111/wrr.12319 ↗
21. 10.1073/pnas.111012110810.1073/pnas.1110121108 ↗
22. 10.1080/0363904080236925510.1080/03639040802369255 ↗
23. 10.1016/j.biomaterials.2015.08.05010.1016/j.biomaterials.2015.08.050 ↗
24. 10.1016/S1381-5148(98)00073-X10.1016/S1381-5148(98)00073-X ↗
25. 10.1002/adfm.20120194510.1002/adfm.201201945 ↗
26. 10.1016/j.biomaterials.2010.04.02010.1016/j.biomaterials.2010.04.020 ↗
27. 10.1002/adma.20090173310.1002/adma.200901733 ↗
28. 10.1016/j.biomaterials.2008.12.03610.1016/j.biomaterials.2008.12.036 ↗
29. 10.1016/j.biomaterials.2011.01.01010.1016/j.biomaterials.2011.01.010 ↗
30. 10.1002/adtp.20190016910.1002/adtp.201900169 ↗
31. 10.1002/marc.20160024410.1002/marc.201600244 ↗
32. 10.1021/acsapm.9b0007110.1021/acsapm.9b00071 ↗
33. 10.1039/b902822f10.1039/b902822f ↗
34. 10.1002/adfm.20120005210.1002/adfm.201200052 ↗
35. 10.1002/jgm.69610.1002/jgm.696 ↗
36. 10.1038/ncomms966310.1038/ncomms9663 ↗
37. 10.1021/bi800538410.1021/bi8005384 ↗
38. 10.1038/s41467-018-06072-w10.1038/s41467-018-06072-w ↗
39. 10.1016/j.jcis.2022.09.01910.1016/j.jcis.2022.09.019 ↗
40. 10.3791/5398810.3791/53988 ↗
41. 10.18632/oncotarget.1515510.18632/oncotarget.15155 ↗
42. 10.1186/s12885-016-2790-310.1186/s12885-016-2790-3 ↗
43. 10.1016/j.jconrel.2013.08.03410.1016/j.jconrel.2013.08.034 ↗
44. 10.1021/nn200007z10.1021/nn200007z ↗
45. 10.1038/s41598-019-56273-610.1038/s41598-019-56273-6 ↗
46. 10.1126/sciadv.abc720910.1126/sciadv.abc7209 ↗
47. 10.1038/ncomms1098010.1038/ncomms10980 ↗
48. 10.1186/s12935-019-0733-110.1186/s12935-019-0733-1 ↗
49. 10.1111/j.1600-0714.2012.01177.x10.1111/j.1600-0714.2012.01177.x ↗
50. 10.1038/nprot.2008.22610.1038/nprot.2008.226 ↗